AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Trial: NCT01636128
Drug: Sulindac
RxNorm normalized name: Sulindac
DrugBank: Sulindac (DB00605)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: 150 mg oral for 15 days, combined with DFMO for 14 days
Trial: NCT02399137
Drug: MM-141
RxNorm normalized name: inositol 141 MG
DrugBank: Inositol (DB13178)
FDA approved: yes
EMA approved: no
PMDA approved: no
Trial: NCT02399137
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT00955513
Drug: diclofenac diethylamine gel 2.32%
FDA approved: no
EMA approved: no
PMDA approved: no
Description: diclofenac diethylamine gel 2.32% twice a day
Trial: NCT00955513
Drug: diclofenac diethylamine gel 2.32%
FDA approved: no
EMA approved: no
PMDA approved: no
Description: diclofenac diethylamine gel 2.32% three times a day
Trial: NCT00955513
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo
Trial: NCT00666965
Drug: SPM 962
FDA approved: no
EMA approved: no
PMDA approved: no
Description: transdermal application, 1 time per day, 0-6.75 mg/body, titration, 6weeks
Trial: NCT02861482
Drug: Blood Product
RxNorm normalized name: Blood product
FDA approved: no
EMA approved: no
PMDA approved: no
Description: transfusion of blood product if necessary no matter which surgical procedure has been taken
Trial: NCT04629846
Drug: QL1209
FDA approved: no
EMA approved: no
PMDA approved: no
Description: QL1209 IV infusion in 3-week cycles. Prior to surgery (neoadjuvant treatment): 840 milligrams (mg) loading dose for Cycle 1, followed by 420 mg for Cycles 2-4.
Trial: NCT01323140
Drug: testosterone matrix transdermal system
RxNorm normalized name: testosterone Transdermal System
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT01371305
Drug: BG00011
FDA approved: no
EMA approved: no
PMDA approved: no
Description: BG00011 will be administered at varying doses via subcutaneous (SC) injection
Trial: NCT01371305
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Sterile normal saline (0.9% Sodium Chloride for Injection) via Subcutaneous (SC) injections.
Trial: NCT00049660
Drug: capecitabine
RxNorm normalized name: Capecitabine
DrugBank: Capecitabine (DB01101)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Trial: NCT00586976
Drug: Normal saline
RxNorm normalized name: Normal Saline Flush
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Normal saline infusion at 4 ml/hour for 64 hours.
Trial: NCT00504894
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: A low dose given intravenously one time for just under an hour while the subject is shown visually stimulating images in an MRI machine.
Trial: NCT04394936
Drug: Placebos
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Sodiumchloride 0,9% solution for injection
Trial: NCT00001967
Drug: HAART
RxNorm normalized name: porcine heart preparation
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT02605174
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Two placebo tablets to match lasmiditan doses.
Trial: NCT01140061
Drug: Placebo Patch
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo patches matching MK-0873 0.05%, 0.5%, or 2% patches
Trial: NCT01140061
Drug: Placebo Cream
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo cream matching MK-0873 0.05%, 0.5%, or 2%
Trial: NCT01140061
Drug: Plain patch
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Plain patch containing no MK-0873 or placebo
Trial: NCT01078844
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Look-alike placebo
Trial: NCT00002921
Drug: therapeutic hydrocortisone
RxNorm normalized name: Moisturel Therapeutic
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT04379076
Drug: Placebos
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intramuscular (IM) placebo (normal saline) at the same frequency
Trial: NCT01587235
Drug: Ezetimibe/simvastatin
RxNorm normalized name: EZETIMIBE/SIMVASTATIN
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Algorithm based treatment using 10/10mg, 10/20mg and 10/40mg ezetimibe/simvastatin combination tablets orally once daily.
Trial: NCT01587235
Drug: Other Statin
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Participants are prescribed a statin (any other than Vytorin) as per routine standard of care
Trial: NCT02217917
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Matched Placebo administered as single dose subcutaneously with rHuPH20.
Trial: NCT02217917
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Matched Placebo administered q12h for 7 days (a total of 13 doses) subcutaneously with rHuPH20.
Trial: NCT02126839
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Matching Placebo delivered via a multidose dry powder inhaler (MDPI).
Trial: NCT02126839
Drug: ProAir HFA inhaler
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Rescue medication, ProAir hydrofluoroalkane (HFA) inhaler, was dispensed at the run-in visit for the relief of asthma symptoms to be administered as needed.
Trial: NCT01735370
Drug: Etodolac Tablets USP 500mg
RxNorm normalized name: etodolac Oral Tablet
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 500 mg tablet once a day
Trial: NCT01735370
Drug: Etodolac Tablets USP 500 mg
RxNorm normalized name: etodolac Oral Tablet
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 500 mg tablet once a day
Trial: NCT00332891
Drug: SR58611A
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT02146625
Drug: CJ-40002
RxNorm normalized name: ethanol
DrugBank: Ethanol (DB00898)
FDA approved: yes
EMA approved: no
PMDA approved: no
Trial: NCT02055300
Drug: LY03005
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT02055300
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT02113358
Drug: Intravenous colloid bolus with Voluven
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT00934674
Drug: SKI-606 (Bosutinib)
RxNorm normalized name: ethanol
DrugBank: Ethanol (DB00898)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Arm 1 - Commercial Tablet manufactured by Excella~Arm 2 - Clinical Tablet manufactured by Wyeth Montreal
Trial: NCT01706783
Drug: Norditropin NordiFlex®
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Subcutaneous (s.c., under the skin) administration daily for 28 days. The daily dosing will be the same as the pre-trial daily dose of human growth hormone (hGH) taken by the adult with growth hormone deficiency
Trial: NCT03489928
Drug: Dinoprostone
RxNorm normalized name: Dinoprostone
DrugBank: Dinoprostone (DB00917)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Prostaglandin E2 - 1-2mg gel manufactured for vaginal use; placed vaginally every 6 hours as needed.
Trial: NCT01106235
Drug: cyclophosphamide
RxNorm normalized name: Cyclophosphamide
DrugBank: Cyclophosphamide (DB00531)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Given IV
Trial: NCT00493818
Drug: GSK690693
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT00474617
Drug: Rocurium
FDA approved: no
EMA approved: no
PMDA approved: no
Description: intravenous (IV) single bolus dose of 0.6 mg.kg-1
Trial: NCT02349685
Drug: 14 day PBMT group
RxNorm normalized name: Streptococcus viridans group
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Rescue therapy using 14 day PBMT regimen \[Proton pump inhibitor (PPI) regular dose b.i.d., tripotassium dicitrate bismuthate 300 mg q.i.d. (three tablets at 30 min before meals and one tablet at 2 hours after dinner), metronidazole 500 mg t.i.d., and tetracycline 500 mg q.i.d\]
Trial: NCT01755455
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Matching placebo capsule
Trial: NCT01106508
Drug: LEQ506
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT03350906
Drug: n3-PUFA
FDA approved: no
EMA approved: no
PMDA approved: no
Description: The DHA/EPA softgels will each contain \~465mg of EPA and \~375mg of DHA for a total daily dosage of 3.4g/day. Additionally, each capsule will contain SCI's proprietary Advance Lipid TechnologiesTM (ALTTM) containing the surfactants polysorbate 80, NF (\~381 mg) and poloxamer 237, NF (\~8.8 mg).
Trial: NCT03350906
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Looks exactly like the study drug but contains soybean oil with no active ingredient.
Trial: NCT01701934
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: One placebo pill daily, for 6 months
Trial: NCT00331188
Drug: Sanvar® (vapreotide)
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT00017290
Drug: cyclophosphamide
RxNorm normalized name: Cyclophosphamide
DrugBank: Cyclophosphamide (DB00531)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Trial: NCT03502902
Drug: HEC 68498
RxNorm normalized name: ALCOHOL 73 L in 100 L TOPICAL GEL [Grand Valley Reagents HEC Hand Sanitizer Gel]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: HEC68498 is a potent,highly selective inhibitor of class 1 isozymes of phosphoinositide 3-kinase/mammalian(PI3K) and of the mammalian target of rapamycin (mTOR). It has shown good activity against fibrosis and inflammation in vitro and in vivo, with a lower effective dose and better efficacy than pirfenidone and nintedanib.
Trial: NCT03502902
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo
Trial: NCT03150628
Drug: HIPEC
RxNorm normalized name: Hyperthermic Intraperitoneal Chemotherapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Hyperthermic intraperitoneal chemotherapy (HIPEC) with 100mg/m2 cisplatin
Trial: NCT04029571
Drug: TCM-FMD
RxNorm normalized name: ethanol
DrugBank: Ethanol (DB00898)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Apply fastening-mimicking diet combined with a dispelling dampness meal replacement. For the convenience of implementation, a cycle of 4 weeks. The first 5 days of each cycle is the calorie restriction stage (daily calorie about 800kcal). The traditional Chinese medicine with dampness effect is used as the main source of calories in this stage. The normal diet is carried out under the guidance of a professional dietitian for the next 23 days. Study for 12 weeks.
Trial: NCT00248716
Drug: Ferrous gluconate and iron polysaccharide complex
RxNorm normalized name: ferrous fumarate / polysaccharide iron complex
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Children with anemia will receive 5mg per kg per day of one of study medications. Treatment period for 3 months
Trial: NCT03204253
Drug: rFSH + r-LH in combination
RxNorm normalized name: pantolactone, (R)-
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 29 women stimulated with rFSH supplemented by rLH in the late follicular phase started at the same time of starting the antagonist administration.
Trial: NCT02087722
Drug: KI1001
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT02087722
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT01656070
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT01437826
Drug: antioxidants
RxNorm normalized name: E Complex with Antioxidants
FDA approved: no
EMA approved: no
PMDA approved: no
Description: tablets composed of 200 mcg selenium \[as l-selenomethionine\], 30 mg zinc, 2 mg vitamin A \[retinol\], 180 mg vitamin C \[ascorbic acid\] and 30 mg vitamin E \[D-α-tocopherol acetate\]
Trial: NCT01437826
Drug: placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: placebo had an identical appearance as intervention
Trial: NCT01493882
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Form = tablet, route = oral administration, once daily from Week 0 to Week 24 for Part 1 and Part 2
Trial: NCT01278082
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Alternating daily dosing with 2 placebo capsules OD and 1 placebo capsule OD every second day.
Trial: NCT01641822
Drug: Placebo to match AZLI
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo to match AZLI 3 times daily combined with diluent administered using an eFlow nebulizer
Trial: NCT03403309
Drug: 1) Inosine 5'-monophosphate
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 1) Subjects are initiated with 1 tablet (500mg of inosine 5'-monophosphate per one tablet) two times per day, and then titrated up by 1 tablet per every visit up to visit 2, i.e. increased up to 2 tablets two times a day by week 6. A maximum limit of elevated serum uric acid level is 9 mg/dL, so that reducing dose of administration may be considered in case of being way over the top of limited level.
Trial: NCT03403309
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 2) Subjects are initiated with 1 tablet (500mg of placebo tablet with inactive therapeutic effect) two times a day, and then titrated up by 1 tablet per every visit up to visit 2, i.e. increased up to 2 tablets two times a day by week 6. A maximum limit of elevated serum uric acid level is 9 mg/dL.
Trial: NCT02251210
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT04122170
Drug: Aspirin (ASA) Oral Tablet - Pre-Treatment
RxNorm normalized name: aspirin Oral Tablet
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Aspirin 81 mg oral tablet; administered daily between Day -7 to the morning before receiving study medication on Day 1, for a total of 8 tablets only.
Trial: NCT04122170
Drug: Placebo (0.9% Sodium chloride) infusion
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 0.9% Sodium chloride Intravenous Infusion over a 16 hour duration
Trial: NCT01665352
Drug: TTP054
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Administered orally once daily for 12 weeks.
Trial: NCT01665352
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Administered orally once daily for 12 weeks.
Trial: NCT01033318
Drug: MK1809
FDA approved: no
EMA approved: no
PMDA approved: no
Description: single oral doses of MK1809
Trial: NCT01033318
Drug: Comparator: Placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo to MK1809
Trial: NCT05338723
Drug: Rosuvastatin 20mg
RxNorm normalized name: ROSUVASTATIN 20MG CAP,SPRINKLE
DrugBank: Rosuvastatin (DB01098)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: 20 mg of oral rosuvastatin 24 hours prior to the first cycle of chemotherapy and once daily for the rest of the follow-up period (6 months).
Trial: NCT01532115
Drug: BIA 9-1067
RxNorm normalized name: Oatmeal 10 mg in 1 mL TOPICAL CREAM [BIA Eczema Relief]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 50 mg and 800 mg of BIA 9-1067 (single-dose)
Trial: NCT01532115
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: single-dose
Trial: NCT01771445
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 100mg, s.c., once only
Trial: NCT01675362
Drug: Antioxidant group
RxNorm normalized name: antioxidant 119
FDA approved: no
EMA approved: no
PMDA approved: no
Description: They will be receive vitamins A, C, E and selenium (Selenium ACE) Dosage: Two tablets before ESWL Then 2 tablets every 8 hours after ESWL for one week
Trial: NCT01675362
Drug: Calcium Channel Blockers
RxNorm normalized name: CALCIUM CHANNEL BLOCKERS
FDA approved: no
EMA approved: no
PMDA approved: no
Description: They will receive Verapamil (Isoptin 80 mg) Dosage: One tablet 2 hours before ESWL Then one tablet every 12 hours after ESWL for one week
Trial: NCT01675362
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: They will receive placebo
Trial: NCT01049113
Drug: ON 013105
RxNorm normalized name: Gel-One
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 2-hour intravenous infusion once a week. Starting dose is 17 mg. Maximum dose will be 1525 mg.
Trial: NCT03233438
Drug: Usual Care
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Usual care as prescribed by the physician as standard of care in clinical practice for the treatment of ABSSSI.
Trial: NCT02001857
Drug: 1 TachoSil hemostatic sponge (9,5 cm x 4,8 cm) placed on each side on the external iliac artery.
FDA approved: no
EMA approved: no
PMDA approved: no
Description: at the end of surgery
Trial: NCT01928368
Drug: AMG 282 Matching Placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Single dose of matching AMG 282 placebo either subcutaneously or intravenously on day 1.
Trial: NCT00854633
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oral, twice per day
Trial: NCT01205477
Drug: EXPERIMENTAL
RxNorm normalized name: WA-001 Experimental Soil Surfactant
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Infiltration of 40 mg of methylprednisolone acetate plus 1 mL of xylocaine and Diclofenac sodium 100 mg PO QD for 10 days
Trial: NCT01205477
Drug: PLACEBO
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Infiltration of 1 mL of xylocaine and Diclofenac sodium 100 mg PO QD for 10 days
Trial: NCT03437824
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 0.9% Sodium Chloride, Once
Trial: NCT03249103
Drug: Placebo oral capsule
RxNorm normalized name: Placebo Oral Capsule
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Matching placebo capsules.
Trial: NCT03688100
Drug: Medication Management
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Collaborative care model will be used. The medication management group will meet with the patient in a one 50 minute in person introductory antidepressant medication treatment session to educate the patient about depression and medication options. Patients will get prescribed a standard of care anti-depressant medication by treating physician, followed by 12 weekly follow up telephone visits, then on a monthly basis for 3 months, and then as needed thereafter.
Trial: NCT00494507
Drug: Placebo (double-blind)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Inactive substance manufactured to look like Dichlorphenamide 50mg tablet
Trial: NCT01577472
Drug: High Dose Placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo is added to a high dose of HMG (450 IU of Merional®) in the early follicular phase of the stimulation (day 3 to 7).
Trial: NCT01577472
Drug: Low dose Placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo is added to a low dose of HMG (150 IU of Merional®) in the early follicular phase of the stimulation (day 3 to 7).
Trial: NCT04005079
Drug: Prednisolone
RxNorm normalized name: Prednisolone
DrugBank: Prednisolone acetate (DB15566)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Standard of Care
Trial: NCT00683969
Drug: placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: po bid for 36 weeks
Trial: NCT00295932
Drug: cyclophosphamide
RxNorm normalized name: Cyclophosphamide
DrugBank: Cyclophosphamide (DB00531)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Given IV
Trial: NCT01416480
Drug: Theobromine 300mg
DrugBank: Theobromine (DB01412)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Capsule, b.i.d.
Trial: NCT03779074
Drug: 10d bismuth quadruple therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: rabeprazole 20 mg b.i.d. plus tripotassium dicitrate bismuthate 300 mg, tetracycline 500 mg and metronidazole 250 mg q.i.d. for 10 days
Trial: NCT03779074
Drug: 14d hybrid therapy
RxNorm normalized name: tetracycline
DrugBank: Tetracycline (DB00759)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: a dual regimen with rabeprazole 20 mg and amoxicillin 1 g b.i.d. for 7 days followed by a quadruple regimen with rabeprazole 20 mg, amoxicillin 1 g, clarithromycin 500 mg and metronidazole 500 mg b.i.d. for 7 days
Trial: NCT03779074
Drug: 14D high-dose dual therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: rabeprazole 20 mg and amoxicillin 750 mg q.i.d. for 14 days
Trial: NCT03235167
Drug: CpG DNA
RxNorm normalized name: Toxoplasma gondii DNA
FDA approved: no
EMA approved: no
PMDA approved: no
Description: CpG DNA concentrate
Trial: NCT03235167
Drug: Placebo - Concentrate
FDA approved: no
EMA approved: no
PMDA approved: no
Description: CpG DNA vehicle
Trial: NCT04305743
Drug: OnabotulinumtoxinA 100 UNT
RxNorm normalized name: onabotulinumtoxinA 100 UNT
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intradetrusor onabotulinumtoxin A is administered cystoscopically with 100 unit dose given as either 5 or 20 injections in a single procedure based on the arm the participant is randomized into.
Trial: NCT03178669
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Solution manufactured to mimic cobitolimod
Trial: NCT02540993
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Matching placebo, oral tablet, once daily in the morning, until the trial was completed provided there were no safety grounds for discontinuing treatment
Trial: NCT00332553
Drug: 17 beta estradiol
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT01438177
Drug: Cyclophosphamide
RxNorm normalized name: Cyclophosphamide
DrugBank: Cyclophosphamide (DB00531)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Trial: NCT00079677
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Matching placebo tablets once daily
Trial: NCT04462939
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: No active ingredients except of 225 μg iodine; One capsule daily, oral
Trial: NCT02982083
Drug: Placebo Oral Tablet
RxNorm normalized name: placebo ORAL TABLET
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 20 patients consume placebo oral tablets daily for one year.
Trial: NCT03318523
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Administered as specified in the treatment arm
Trial: NCT01206530
Drug: Leucovorin
RxNorm normalized name: Leucovorin
DrugBank: Leucovorin (DB00650)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Dose: 400mg/m2 Route IV infusion over 2 hours Treatment Administration: Day 1